GlassScriptPhysician profile
Esra S Onat
NPI 1710912902
$2,575.39
in general payments reported to CMS, 2019-2025
27 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.96 · 2020: $310 · 2021: $299 · 2022: $441 · 2023: $318 · 2024: $502 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $498.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $323.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $316.49 | 2020-2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.34 | 2020-2023 | Trulance, Xifaxan |
| Daiichi Sankyo INC. | $224.95 | 2020-2023 | Injectafer |
| Ibsa Pharma INC. | $117.56 | 2019-2025 | Licart, Flector, Tirosint |
| Kvk-Tech, INC. | $92.71 | 2024 | |
| Allergan, INC. | $77.28 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $71.15 | 2021-2024 | Contrave, Onzetra Xsail |
| Acella Pharmaceuticals, LLC | $64.74 | 2024-2025 | NP Thyroid 60 |
| Lilly USA, LLC | $55.85 | 2024-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $54.19 | 2020 | |
| Cleerly, INC. | $41.08 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Abbvie INC. | $41.01 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $40.95 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $36.35 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $33.48 | 2024 | Nuzyra |
| Renalytix Ai, INC. | $31.83 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Cumberland Pharmaceuticals, INC. | $30.38 | 2025 | Kristalose |
| Abbott Laboratories | $24.04 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $20.52 | 2022 | |
| Seqirus USA INC | $19.00 | 2025 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $17.91 | 2025 | Lagevrio |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2023 | Hyqvia |
| Alfasigma USA, INC. | $14.94 | 2021 | |
| Pfizer INC. | $14.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esra Onat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.